Detailed Information on Publication Record
2002
Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations.
BÜCHLER, Tomáš and Roman HÁJEKBasic information
Original name
Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations.
Authors
BÜCHLER, Tomáš (703 Slovakia) and Roman HÁJEK (203 Czech Republic, guarantor)
Edition
Medical Oncology, 2002, 1357-0560
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.447
RIV identification code
RIV/00216224:14110/02:00007783
Organization unit
Faculty of Medicine
Keywords in English
dendritic cells; multiple myeloma; immunotherapy; cytotoxic T-cells; tumor immunology
Změněno: 21/5/2003 07:53, Jana Mamulová
Abstract
V originále
Dendritic cells (DCs) are antigen-presenting cells that play a key role in the induction of cytotoxic T-lymphocytes. Adjuvant immunotherapy with antigen-loaded DCs represents an attractive anticancer strategy for multiple myeloma (MM). Autologous DCs loaded with idiotypic protein or other myeloma-associated antigen have been used in several clinical trials. Preclinical and first clinical experience have provided valuable insights in the mechanisms of cellular immunity, but few, if any, patients with MM benefited from such vaccination. Taken together, the data suggest that antitumor T-cell responses fail in MM because of a deregulated cytokine network, downregulation of costimulatory surface receptor expression, and changes in T-cell repertoire, enabling tumor cells to escape immune effectors by preventing the antitumor immune response. We discuss current clinical protocols for DC-based immunotherapy in MM and review some strategies that may increase the efficacy of DC vaccines.
Links
| GA301/00/0405, research and development project |
|